Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
opioid |
| gptkbp:approvalYear |
2008
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A06AH01
|
| gptkbp:brand |
gptkb:Relistor
|
| gptkbp:CASNumber |
73360-69-5
|
| gptkbp:chemicalFormula |
C21H26NO4+
|
| gptkbp:contraindication |
known or suspected gastrointestinal obstruction
|
| gptkbp:developedBy |
gptkb:Progenics_Pharmaceuticals
|
| gptkbp:hasSMILES |
C[C@]12CC[C@H]3[C@H]([C@@H]1CCN2C)Cc4ccc(O)c(C3=O)c4
|
| https://www.w3.org/2000/01/rdf-schema#label |
methylnaltrexone
|
| gptkbp:KEGGID |
D08144
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
peripherally acting mu-opioid receptor antagonist
|
| gptkbp:molecularWeight |
356.44 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL1201192
5362440 DB06800 |
| gptkbp:routeOfAdministration |
oral
subcutaneous injection |
| gptkbp:sideEffect |
nausea
abdominal pain flatulence |
| gptkbp:UNII |
7LQ0516E0U
|
| gptkbp:usedFor |
opioid-induced constipation
|
| gptkbp:bfsParent |
gptkb:Relistor
|
| gptkbp:bfsLayer |
7
|